Sichuan Huiyu Pharmaceutical Co Ltd Cash Flow Conversion Efficiency
Sichuan Huiyu Pharmaceutical Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Sichuan Huiyu Pharmaceutical Co Ltd (688553) has a cash flow conversion efficiency ratio of 0.016x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥58.54 Million ≈ $8.57 Million USD) by net assets (CN¥3.72 Billion ≈ $544.50 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Sichuan Huiyu Pharmaceutical Co Ltd (2017–2024)
Cash flow conversion efficiency of Sichuan Huiyu Pharmaceutical Co Ltd from 2017 to 2024. This chart illustrates how Sichuan Huiyu Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 688553 live share price for real-time trading data and today's change.
Sichuan Huiyu Pharmaceutical Co Ltd Cash Flow Conversion Ratio Explained
Sichuan Huiyu Pharmaceutical Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Sichuan Huiyu Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sichuan Huiyu Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency. Also see 688553 stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SEP Analytical (Shanghai) Co. Ltd.
SHE:301228
|
N/A |
|
Wuxi Jinyang New Materials Co. Ltd. A
SHE:301210
|
N/A |
|
ZYLOX-TONBRDG.MED.TECH.H1
F:818
|
N/A |
|
engcon AB Cl B
ST:ENGCON-B
|
0.079x |
|
Pexip Holding ASA
OL:PEXIP
|
0.196x |
|
EcoRodovias Infraestrutura e Logística S.A
SA:ECOR3
|
0.322x |
|
Phreesia Inc
NYSE:PHR
|
0.048x |
|
Winall Hi tech Seed
SHE:300087
|
0.016x |
Annual Cash Flow Conversion Efficiency for Sichuan Huiyu Pharmaceutical Co Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of Sichuan Huiyu Pharmaceutical Co Ltd from 2017 to 2024. Review Sichuan Huiyu Pharmaceutical Co Ltd free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥3.97 Billion ≈ $581.43 Million |
CN¥242.96 Million ≈ $35.55 Million |
0.061x | +244.81% |
| 2023-12-31 | CN¥3.77 Billion ≈ $552.32 Million |
CN¥66.93 Million ≈ $9.79 Million |
0.018x | -66.02% |
| 2022-12-31 | CN¥3.72 Billion ≈ $544.07 Million |
CN¥194.06 Million ≈ $28.40 Million |
0.052x | -58.39% |
| 2021-12-31 | CN¥3.56 Billion ≈ $520.72 Million |
CN¥446.36 Million ≈ $65.32 Million |
0.125x | -75.70% |
| 2020-12-31 | CN¥751.48 Million ≈ $109.97 Million |
CN¥387.95 Million ≈ $56.77 Million |
0.516x | -35.33% |
| 2019-12-31 | CN¥408.65 Million ≈ $59.80 Million |
CN¥326.22 Million ≈ $47.74 Million |
0.798x | +193.22% |
| 2018-12-31 | CN¥-150.70 Million ≈ $-22.05 Million |
CN¥129.06 Million ≈ $18.89 Million |
-0.856x | -1305.63% |
| 2017-12-31 | CN¥-185.32 Million ≈ $-27.12 Million |
CN¥-13.16 Million ≈ $-1.93 Million |
0.071x | -- |
About Sichuan Huiyu Pharmaceutical Co Ltd
Sichuan Huiyu Pharmaceutical Co., Ltd. research and develops, produces, and sells anti-tumor injection in China and internationally. The company offers injection drug products, such as pemetrexed disodium, methrotraxate, docetaxel, azacitidine, oxaliplatin, cyclophosphamide, irinotecan hydrochloride, paclitaxel, bendamustine hydrochloride, decitabine, palonosetron hydrochloride, plerixafor, levet… Read more